-
Antisense & RNAi Therapeutics Market Report 2024, Featuring Profiles of Alnylam Pharmaceuticals, Arbutus Biopharma, Benitec Biopharma, GSK, Ionis Pharmaceuticals, Sanofi, Sarepta Therapeutics & More - ResearchAndMarkets.com
11 Dec 2024 17:57 GMT
… cardiovascular, respiratory, neurodegenerative, and genetic disorders. Its precision in … 3. Key Global Players
Alnylam Pharmaceuticals
Arbutus Biopharma
Benitec … Cardiometabolic & Renal Disorders
Genetic Disorders
Infectious Diseases
Respiratory …
-
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
25 Nov 2024 12:15 GMT
… messenger RNA (mRNA) – the genetic precursors that encode for disease … of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY … successfully execute on its “Alnylam P5x25” strategy; Alnylam’s ability to successfully …
-
FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam
23 Nov 2024 00:54 GMT
The FDA approved BridgeBio’s acoramidis in a rare, genetic heart disease that’s expected to become an intense area of market competition, and a broad label …
Sign up to read this article for free.
Get free access to a limited number of …
-
Alnylam reports interim phase 1 data of nucresiran showing rapid knockdown of TTR that is sustained at six months following a single dose
19 Nov 2024 13:31 GMT
… amyloidosis. As part of Alnylam’s proprietary IKARIA platform, … mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, … RNA (mRNA) – the genetic precursors that encode for disease … of patients with genetic and other diseases.
Alnylam has led …
-
Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
17 Nov 2024 14:34 GMT
… messenger RNA (mRNA) – the genetic precursors that encode for disease … of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY … successfully execute on its “Alnylam P5x25” strategy; Alnylam’s ability to successfully …
-
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
01 Nov 2024 19:59 GMT
… study designs that allow for genetically or biomarker-defined patient … Unraveling the Financial Story of Alnylam Pharmaceuticals
Market Capitalization Analysis: Falling … .
Positive Revenue Trend: Examining Alnylam Pharmaceuticals's financials over …
-
Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity
31 Oct 2024 12:05 GMT
… messenger RNA (mRNA) – the genetic precursors – that encode for disease … of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq … execute on its “Alnylam P5x25” strategy; Alnylam’s ability to discover …
-
Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024
30 Oct 2024 12:12 GMT
… silencing messenger RNA (mRNA) – the genetic precursors that encode for disease … of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY … late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to …
-
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
16 Oct 2024 12:16 GMT
… messenger RNA (mRNA) – the genetic precursors that encode for disease … of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY … successfully execute on its “Alnylam P5x25” strategy; Alnylam’s ability to successfully …
-
Advances in Genetic Engineering Driving Gene Therapy Market at 21.4% CAGR by 2031
11 Oct 2024 13:07 GMT
… public awareness and knowledge, genetic testing is becoming increasingly important … investigate gene therapies for rare genetic diseases, capitalizing on their … (US)
• Bristol-Myers Squibb (US)
• Alnylam Pharmaceuticals, Inc. (US)
• Sarepta Therapeutics …
About
© 1995-2025